Study #2022-0408
A phase 1/2 immunotherapy study of Evofosfamide in combination with Zalifrelimab and Balstilimab in patients with Advanced Solid Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Evofosfamide, Zalifrelimab, Balstilimab
Description
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Study phase:
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-939-2381
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.